PSTV_OUT_1 [2025-03-25 09:39:19 -0400] 2089 Bytes | 608 tokens | Cum: 608 tkns (7.60% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at PLUS THERAPEUTICS (PSTV) which is at 1.415 up from 1.14. So, I pulled together a bunch of data for you to look over real fast. It's still early, 9:39:17 AM on Tue Mar 25, 2025 -0400. So, what's the verdict? You're the expert!

Here's the first list of news for PLUS THERAPEUTICS:

C1 - Mar-21-25 12:17PM - PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
C2 - Mar-21-25 12:17PM 06:34AM - Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?
C3 - Mar-20-25 07:30AM - Plus Therapeutics Introduces REYOBIQ , FDA-Accepted Proprietary Name for Lead Drug Candidate
C4 - Mar-19-25 07:30AM - Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
C5 - Mar-11-25 11:00AM - D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
C6 - Mar-10-25 07:30AM - Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
C7 - Mar-07-25 01:49PM - Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday
C8 - Mar-07-25 01:49PM 07:33AM - FDA ODD given to Plus Therapeutics injectable radiotherapy

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on PLUS THERAPEUTICS (PSTV)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PSTV_OUT_3 [2025-03-25 09:39:25 -0400] 1047 Bytes | 314 tokens | Cum: 924 tkns (11.55% of 8k)
==========================================================================

Showing C3 (chunk 1 of 5): C3:
**Plus Therapeutics Introduces REYOBIQ , FDA-Accepted Proprietary Name for Lead Drug Candidate**
Date: Mar-20-25 07:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046120/0/en/Plus-Therapeutics-Introduces-REYOBIQ-FDA-Accepted-Proprietary-Name-for-Lead-Drug-Candidate.html

March 20, 2025 07:30 ET| Source:Plus Therapeutics Inc.Plus Therapeutics Inc.

REYOBIQ™ (rhenium Re186obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM)

HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) --Plus Therapeutics, Inc.(Nasdaq:PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company’s

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PSTV_OUT_5 [2025-03-25 09:39:26 -0400] 950 Bytes | 287 tokens | Cum: 1304 tkns (16.30% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-23T02:18:07Z - Plus Therapeutics Inc.: Plus Therapeutics Introduces REYOBIQ, FDA-Accepted Proprietary Name for Lead...
A2 - 2025-03-21T21:05:50Z - 12 Health Care Stocks Moving In Friday's After-Market Session - Aspira Womens Health (NASDAQ:AWH), C...
A3 - 2025-03-21T20:02:35Z - Top Small Cap Stocks To Watch Today - March 20th...
A4 - 2025-03-21T17:21:00Z - PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug...
A5 - 2025-03-21T10:21:07Z - Why Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - AuthID (NAS...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PSTV_OUT_7 [2025-03-25 09:39:32 -0400] 1038 Bytes | 304 tokens | Cum: 1610 tkns (20.12% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Plus Therapeutics Inc.: Plus Therapeutics Introduces REYOBIQ, FDA-Accepted Proprietary Name for Lead Drug Candidate**Date: 2025-03-23Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-03/64881487-plus-therapeutics-inc-plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate-399.htmREYOBIQ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM)

HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PSTV_OUT_9 [2025-03-25 09:39:34 -0400] 988 Bytes | 286 tokens | Cum: 1996 tkns (24.95% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-04T19:06:00Z - Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
B2 - 2024-07-02T11:30:00Z - Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
B3 - 2024-06-07T11:30:00Z - Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
B4 - 2024-05-17T21:00:00Z - Plus Therapeutics Announces New Employment Inducement Grants
B5 - 2024-05-15T20:15:00Z - Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
B6 - 2024-05-13T11:30:00Z - Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PSTV_OUT_11 [2025-03-25 09:39:38 -0400] 686 Bytes | 172 tokens | Cum: 2170 tkns (27.12% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/04/3036891/0/en/Plus-Therapeutics-Secures-Private-Placement-of-Approximately-15-Million-in-Gross-Proceeds.htmlPlus Therapeutics, a clinical-stage pharmaceutical company, announced the pricing of a $15.0 million private placement. The funds will be used to advance the company's central nervous system cancer therapies and meet key near-term milestones.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PSTV_OUT_13 [2025-03-25 09:39:40 -0400] 1127 Bytes | 281 tokens | Cum: 2497 tkns (31.21% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-04 8-K Item1.01 Entry Into a Material Definitive Agrmt.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with accredited investors, including certain existing stockholders o...

S2 - 2025-03-04 8-K Item1.01 Entry Into a Material Definitive Agrmt.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with accredited investors, including certain existing stockholders o...

S3 - 2025-03-04 8-K Item1.01 Entry Into a Material Definitive Agrmt.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with accredited investors, including certain existing stockholders o...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PSTV_OUT_15 [2025-03-25 09:39:42 -0400] 1038 Bytes | 239 tokens | Cum: 2738 tkns (34.23% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item1.01 Entry Into a Material Definitive Agreement.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agreement) with accredited investors, including certain existing stockholders of the Company, identified on the signature page thereto (collectively, the Purchasers) for a private placement of securities (the Private Placement) for gross proceeds expected at closing of approximately $15.0 million. The Securities Purchase Agreement, provides for the sale and issuance by the Company of an aggregate of 28,042,140 shares (the Private Placement Shares) of the Companys common stock, par value $0.001 per share (Common Stock), or, at the election of each Purchaser, prefunded warrants to purchase Common Stock (the Prefunded Warrants), exercisable immediately at an exercise price of $0.001 per sh

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PSTV_OUT_17 [2025-03-25 09:39:43 -0400] 1038 Bytes | 239 tokens | Cum: 2979 tkns (37.24% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): are (the Prefunded Warrant Shares), with each Private Placement Share or Prefunded Warrant accompanied by (i) a Series A common warrant (the Series A Warrants) to purchase one share of Common Stock (the Series A Warrant Shares), and (ii) one Series B common warrant (the Series B Warrants) to purchase one share of Common Stock (the Series B Warrant Shares, and together with the Series A Warrant Shares, the Common Warrant Shares). The Private Placement Shares, Prefunded Warrants, Prefunded Warrant Shares, Series A Warrants, Series B Warrants, and the Common Warrant Shares are collectively referred to herein as the Securities.

The combined purchase price of $0.66 for each Private Placement Share or $0.659 for each Prefunded Warrant in the Private Placement, together with one accompanying Series A Warrant and one accompanying Series B Warrant, represents the applicable Minimum Price in acc

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PSTV_OUT_19 [2025-03-25 09:39:48 -0400] 1038 Bytes | 233 tokens | Cum: 3214 tkns (40.17% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ordance with Listing Rule 5635(d) of The Nasdaq Stock Market LLC (Nasdaq).

The initial exercise price of each Series A Warrant issued in the Private Placement is $1.32 per share of Common Stock. The Series A Warrants are exercisable only following stockholder approval and expire five (5) years thereafter. The number of securities issuable under the Series A Warrant is subject to adjustment as described in more detail in the Series A Warrant. The Series A Warrant exercise price and the related number of shares of Common Stock issuable upon exercise are subject to a reset provision upon certain events and are subject to anti-dilution protection upon any subsequent transaction at a fixed price lower than the warrant exercise price then in effect, as more fully described in the Series A Warrant.

The initial exercise price of each Series B Warrant issued in the Private Placement is $1.98

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PSTV_OUT_21 [2025-03-25 09:40:02 -0400] 5110 Bytes | 1497 tokens | Cum: 4789 tkns (59.86% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+----------------------+----------------------+------------------------+------------------------+------------------------+
| Volume: 0 | SMA50: 4.65% | Market Cap: 13.43M | Option/Short: No / Yes | Sales past 5Y: 474.41% | Sales Surprise: -0.70% |
+--------------------+----------------------+----------------------+------------------------+------------------------+------------------------+
| Avg Volume: 15.67M | SMA200: -17.62% | Shs Outstand: 11.79M | Short Float: 1.22% | Employees: 20 | EPS Surprise: 34.22% |
+--------------------+----------------------+----------------------+------------------------+------------------------+------------------------+
| Rel Volume: 0.00 | Perf Week: 94.54% | Shs Float: 11.48M | Short Ratio: 0.01 | Debt/Eq: - | P/E: - |
+--------------------+----------------------+----------------------+------------------------+------------------------+------------------------+
| RSI (14): 52.82 | Perf Month: -5.00% | Inst Own: 16.02% | Short Interest: 0.14M | Sales Y/Y TTM: 52.63% | Earnings: Mar 27 AMC |
+--------------------+----------------------+----------------------+------------------------+------------------------+------------------------+
| ATR (14): 0.36 | Perf Quarter: 14.00% | Insider Own: 2.55% | Beta: 0.67 | ROE: -522.50% | |
+--------------------+----------------------+----------------------+------------------------+------------------------+------------------------+
| SMA20: 24.89% | Index: - | Insider Trans: 0.00% | Sales Q/Q: 17.42% | ROI: - | |
+--------------------+----------------------+----------------------+------------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Clowes Howard (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Sims Andrew John Hugh MacIntyre (Chief Financial Officer) on 2025-02-18
- Stock Option (Right to Buy): 60020 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Hawkins Richard J (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Lenk Robert P (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by HEDRICK MARC H (Chief Executive Officer) on 2025-02-18
- Stock Option (Right to Buy): 400489 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: PLUS THERAPEUTICS, Inc. Common Stock
Market Cap: 6721819.619999999
Shares Outstanding: 5896333
Sector: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1456000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -2874000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.4395
Average Volume: 42096811.95
30-Day High: 1.57
30-Day Low: 0.3022

[Detailed Financials: Q3 2024]
- Total Assets: $6,978,000.0
- Total Liabilities: $12,152,000.0
- Total Equity: $-5,174,000.0
- Current Assets: $5,364,000.0
- Current Liabilities: $12,112,000.0

[Income Statement: Q3 2024]
- Revenue: $1,456,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-3,689,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $11,212,000.0
- Total Liabilities: $18,837,000.0
- Total Equity: $-7,625,000.0
- Current Assets: $9,380,000.0
- Current Liabilities: $18,787,000.0

[Income Statement: Q2 2024]
- Revenue: $1,279,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.45

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $2,011,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PSTV_OUT_23 [2025-03-25 09:40:04 -0400] 676 Bytes | 167 tokens | Cum: 5200 tkns (65.00% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PSTV_IN_25 [2025-03-25 09:40:05 -0400] 126 Bytes | 29 tokens | Cum: 5257 tkns (65.71% of 8k)
==========================================================================

====================================
[2025-03-25 06:40:05] # Analysis Completed
Elapsed Time: 48.62 seconds